Dexcom
DXCM
$83.02
+0.44%
DexCom, Inc. is a medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes, offering an alternative to traditional blood glucose meters. As a market leader in the CGM space, DexCom differentiates itself through its advanced sensor technology and integration with insulin pumps from partners like Insulet and Tandem, enabling automated insulin delivery. The current investor narrative centers on the company's expansion into the over-the-counter (OTC) market with its Stelo glucose monitor, which recently received FDA clearance for pediatric use, significantly broadening its addressable market. Additionally, the stock has seen a sharp rally in late July 2026, driven by strong quarterly results and positive analyst sentiment, though it faces competitive pressures and regulatory scrutiny.…
DXCM
Dexcom
$83.02
Related headlines
Investment Opinion: Should I buy DXCM Today?
Based on the analysis, DXCM is rated a Buy. The company's accelerating revenue growth (15.1% YoY), expanding gross margins (62.9%), and attractive PEG ratio (0.67x) support a positive outlook. The analyst consensus is Strong Buy with an average target of $86.16, implying a modest 3.2% upside from the current price of $83.45.
Sign up to view all
DXCM 12-Month Price Forecast
The AI model assesses DXCM as bullish with medium confidence, driven by strong fundamental momentum and a favorable valuation relative to growth. However, the high volatility and competitive risks temper confidence. An upgrade to high confidence would require sustained revenue growth above 20% and margin stability, while a downgrade would occur if growth falls below 10% or margins deteriorate.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Dexcom's 12-month outlook, with a consensus price target around $93.44 and implied upside of +12.6% versus the current price.
Average Target
$93.44
0 analysts
Implied Upside
+12.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$79 - $115
Analyst target range
The target price range spans from a low of $65.00 to a high of $112.00, indicating a wide dispersion of 72.3% between the lowest and highest estimates. The high target of $112.00 assumes significant multiple expansion and accelerating growth, likely driven by the success of Stelo in the OTC market and potential international expansion. The low target of $65.00 prices in competitive pressures from Abbott's Libre and potential reimbursement challenges, which could compress margins. The wide spread suggests high uncertainty about the company's future growth trajectory, but the recent pattern of ratings shows no downgrades, with all actions in the past three months being reaffirmations or upgrades, signaling stable or improving analyst conviction.
Bulls vs Bears: DXCM Investment Factors
DexCom presents a compelling growth story with accelerating revenue, expanding margins, and a new OTC catalyst, but faces valuation and competitive risks. The bull case is currently stronger, supported by strong fundamentals and analyst optimism, yet the stock's premium valuation and competitive pressures warrant caution. The key tension is whether DexCom can sustain its growth acceleration and successfully capture the OTC market without margin erosion, which will determine if the current valuation is justified.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 15.1% YoY to $1.19B, up from 4.6% growth in Q1 2025, indicating strong demand for CGM systems and successful market expansion.
- Expanding Gross Margins: Gross margin improved to 62.9% in Q1 2026 from 56.9% in Q1 2025, driven by better product mix and manufacturing efficiencies, enhancing profitability.
- OTC Market Catalyst: FDA clearance for Stelo in pediatric use (June 2026) opens a new large market segment, potentially driving significant volume growth beyond traditional diabetes patients.
- Attractive Valuation on PEG: PEG ratio of 0.67x suggests the stock is undervalued relative to its growth rate, making it a compelling GARP opportunity despite a trailing PE of 31x.
Bearish
- High Valuation Multiple: Trailing PE of 31x and forward PE of 26.8x are premium to the broader market, leaving little room for error if growth disappoints.
- Intense Competition: Abbott's Libre and other competitors pose a threat, potentially pressuring market share and pricing, as reflected in the analyst low target of $65 (22% downside).
- Regulatory and Reimbursement Risks: Changes in reimbursement policies or regulatory hurdles could impact adoption and margins, a key concern given the company's reliance on insurance coverage.
- High Volatility and Drawdown Risk: The stock experienced a -38.8% max drawdown over the past year, indicating significant price swings that could test investor patience.
DXCM Technical Analysis
DexCom's stock is in a strong uptrend, with the current price of $83.45 representing a 3.3% gain over the past year, though it has significantly outperformed the S&P 500's 18.2% gain over the same period, resulting in a negative relative strength of -14.9%. The stock is trading at 98.5% of its 52-week range (between $54.11 and $84.70), indicating it is near its highs, which suggests strong momentum but also potential overextension. The 1-year price change of 3.3% masks a volatile journey, with the stock experiencing a maximum drawdown of -38.8% during the period, highlighting the high volatility inherent in this name.
Beta
1.41
1.41x market volatility
Max Drawdown
-38.8%
Largest decline past year
52-Week Range
$54-$88
Price range past year
Annual Return
+8.7%
Cumulative gain past year
| Period | DXCM Return | S&P 500 |
|---|---|---|
| 1m | +12.8% | +2.8% |
| 3m | +37.0% | +4.2% |
| 6m | +18.7% | +11.3% |
| 1y | +8.7% | +21.5% |
| ytd | +24.8% | +12.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DXCM Fundamental Analysis
DexCom's revenue trajectory is robust, with Q1 2026 revenue of $1.19 billion, representing a 15.1% year-over-year growth rate, accelerating from the 4.6% growth seen in Q1 2025. The multi-quarter trend shows consistent expansion, with revenue growing from $1.04 billion in Q1 2025 to $1.19 billion in Q1 2026, a 15.1% increase. This growth is driven by strong demand for its CGM systems, particularly the G7 series, and the recent expansion into the OTC market with Stelo, which received pediatric clearance in June 2026. The company's gross margin improved to 62.9% in Q1 2026, up from 56.9% in Q1 2025, reflecting better product mix and manufacturing efficiencies.
Quarterly Revenue
$1.2B
2026-03
Revenue YoY Growth
+15.0%
YoY Comparison
Gross Margin
62.9%
Latest Quarter
Free Cash Flow
$1.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DXCM Overvalued?
Given DexCom's positive net income, the primary valuation metric selected is the price-to-earnings (PE) ratio. The trailing PE is 31.0x, while the forward PE is 26.8x, indicating that the market expects earnings growth of approximately 15.7% over the next year. This forward discount suggests that investors are pricing in continued strong performance, but the gap is not excessive, implying a balanced growth expectation. The PEG ratio of 0.67x, which is below 1, suggests that the stock is undervalued relative to its growth rate, making it an attractive growth-at-a-reasonable-price (GARP) candidate.
PE
31.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 23x~223x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, DexCom carries a moderate debt-to-equity ratio of 0.51, but its strong free cash flow of $1.43B TTM provides a cushion. The company's profitability is solid with a net margin of 17.9%, yet its reliance on continued growth to justify a PE of 31x poses a risk if growth decelerates. Revenue concentration in the CGM market and dependence on reimbursement policies add financial vulnerability, as any adverse changes could impact earnings significantly.
FAQ
Key risks include competitive pressure from Abbott's Libre, which could erode market share and pricing power. Regulatory and reimbursement changes could impact adoption and margins. Financially, the company's high valuation leaves little room for error, and its volatility (max drawdown -38.8%) poses a risk. Additionally, any slowdown in growth could lead to multiple compression.
The 12-month forecast is moderately bullish, with a base case target of $86.16 (50% probability), a bull case of $112 (30% probability), and a bear case of $65 (20% probability). The most likely scenario is steady growth around 15%, supported by strong fundamentals and analyst optimism. However, the wide target range reflects uncertainty about competitive and regulatory developments.
DXCM's trailing PE of 31x is above the market average, but its forward PE of 26.8x and PEG of 0.67x suggest it is undervalued relative to its growth rate. Compared to peers, the stock trades at a premium, reflecting expectations of continued growth. The market is pricing in a 15.7% earnings growth, which is achievable given current trends, making the valuation fair to slightly undervalued.
DXCM is a good buy for investors seeking growth with reasonable valuation, as indicated by its PEG ratio of 0.67x and strong analyst consensus. The stock offers a 3.2% upside to the average target of $86.16, but carries downside risk to $65 if competitive pressures intensify. It is suitable for those with a long-term horizon and tolerance for volatility, but may not be ideal for risk-averse investors.
DXCM is better suited for long-term investment given its growth trajectory and expanding market opportunities. The stock's high volatility (beta not provided but implied by drawdowns) makes it risky for short-term trading. A minimum holding period of 3-5 years is recommended to ride out volatility and capture the benefits of OTC market expansion and international growth.